Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting
Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting
Oak Ridge, TN, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Mid-Winter and American College Nuclear Medicine (ACNM) Annual Meeting at the Hilton Orlando Lake Buena Vista in Orlando, FL, February 1-3, 2024.
田納西州橡樹嶺，2024 年 1 月 29 日（GLOBE NEWSWIRE）— 達克索公司 全球血容量測量技術領導者納斯達克股票代碼：DXR）今天宣佈，它將參加2024年2月1日至3日在佛羅里達州奧蘭多布埃納維斯塔希爾頓酒店舉行的核醫學與分子成像學會（SNMMI）仲冬和美國大學核醫學（ACNM）年會。
"This conference presents an exciting opportunity to raise awareness and educate SNMMI and ACNM members about the significant impact of our blood volume diagnostic. It underscores their crucial role in providing clinicians with precise information to optimize fluid management treatment, leading to significant reductions in mortality, hospital readmission, length of stay, and costs," said Kathryn Kornafel, Daxor's VP of Marketing and Commercial Development.
“本次會議爲提高認識，教育SNMMI和ACNM成員了解我們的血容量診斷的重大影響提供了一個激動人心的機會。它突顯了他們在爲臨床醫生提供精確信息以優化液體管理治療，從而顯著降低死亡率、再入院、住院時間和成本方面的關鍵作用。” 達克索營銷和商業開發副總裁凱瑟琳·科納費爾說。
The Company will be exhibiting at Booth #32.
該公司將在 #32 號展位展出。
Register for the conference HERE.
註冊參加會議 這裏。
About the Society of Nuclear Medicine and Molecular Imaging
關於核醫學與分子影像學會
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. SNMMI's members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit .
核醫學與分子影像學會（SNMMI）是一家國際科學和醫學組織，致力於推進核醫學和分子成像的發展，這是精準醫療的重要組成部分，允許爲個體患者量身定製診斷和治療，以實現最佳結果。SNMMI的成員通過制定指南、通過期刊和會議共享信息以及領導有關影響分子成像和療法研究與實踐的關鍵問題的宣傳，爲分子成像和核醫學實踐設定了標準。欲了解更多信息，請訪問 。
About the American College of Nuclear Medicine
關於美國核醫學院
ACNM is composed of physicians and other nuclear medicine professionals dedicated to enhancing the practice of nuclear medicine through study, education, and improvement of clinical practice. Our goal is to assure a legislative, legal, regulatory, and economic framework that encourages and makes practicable the safe, appropriate use of nuclear medicine procedures to improve the quality of health care service available to patients. For more information, visit .
ACNM 由醫生和其他核醫學專業人員組成，致力於通過研究、教育和改善臨床實踐來加強核醫學實踐。我們的目標是確保立法、法律、監管和經濟框架，鼓勵並使安全、適當使用核醫學程序來提高患者可獲得的醫療服務質量並使之切實可行。欲了解更多信息，請訪問 。
About Daxor Corporation
關於達克索公司
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100 (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor's vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor's innovative technology HERE.
達克索公司（納斯達克股票代碼：DXR）是血容量測量技術的全球領導者，專注於血容量測試創新。我們開發並銷售 BVA-100 （血容量分析儀），美國食品藥品管理局批准的唯一一項診斷性血液檢測，可與患者特定的標準相比，提供安全、準確、客觀的血容量狀態和成分定量。美國領先的醫院中心已經進行了超過65,000次檢測，提高了各種手術和醫療條件下的醫院績效指標，包括顯著降低心力衰竭和重症監護的死亡率和再入院率。在美國國立衛生研究院的支持下，達克索正在心力衰竭治療領域進行多項試驗，並與美國國防部簽訂了開發分析儀的合同，以改善戰鬥傷亡護理。Daxor的使命是通過血容量分析實現最佳的液體管理，從而推動醫療保健的發展。達克索的視野是所有人的最佳血容量。欲了解更多信息，請訪問我們的網站 daxor.com。註冊接收有關 Daxor 創新技術的新聞 這裏。
Forward-Looking Statements
前瞻性陳述
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
本新聞稿中的某些陳述可能包括1995年《私人證券訴訟改革法》所指的前瞻性陳述，包括但不限於有關僱用銷售人員和擴大分銷渠道的影響的陳述。前瞻性陳述是基於當前預期和假設的關於未來事件的預測、預測和其他陳述，因此受到風險和不確定性的影響。許多因素可能導致未來的實際事件與本新聞稿中的前瞻性陳述存在重大差異，包括但不限於與我們的上市後臨床數據收集活動相關的風險、我們的產品對患者的益處、我們對產品開發和商業化工作的期望、我們提高市場和醫生對我們產品的接受度的能力、潛在的競爭產品供應、知識產權保護、美國食品藥品管理局監管行動、我們整合收購的能力企業、我們對與被收購企業的預期協同效應和收益的預期，以及我們在向美國證券交易委員會提交的文件中描述的其他風險和不確定性。前瞻性陳述僅代表截至發表之日。達克索不承擔任何公開更新或修改任何前瞻性陳述的義務，無論是由於新信息、未來事件還是其他原因。
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
516-222-2560
brets@coreir.com
投資者關係聯繫人：
佈雷特·夏皮羅
CORE IR 高級管理合夥人
516-222-2560
brets@coreir.com
譯文內容由第三人軟體翻譯。